Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights May 11, 2022
Neuro player Jazz Pharmaceuticals Dives into Immuno-Oncology, Inking Cytokine Pact with Werewolf April 8, 2022
Werewolf Therapeutics and Jazz Pharmaceuticals Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule April 8, 2022
Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-124 in Delivering IL-2 Selectively to the Tumor Microenvironment March 17, 2022
